Human Impact Exposure Onboard High-Speed Boats
Launched by GÖTEBORG UNIVERSITY · Mar 24, 2022
Trial Information
Current as of November 11, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is an international, observational study called the Multi-Agency Study on Human Impact Exposure Onboard High-Speed Boats (MASHIEN). Researchers want to learn which real-life impact forces on high-speed boats lead to pain or injury, by measuring what happens on the boats and to the people onboard in everyday work. They’ll analyze details like how hard impacts are, how quickly they happen, the direction of the force, and how long they last, with the goal of defining what levels are safe and maybe creating a new way to measure impact exposure.
About 250 healthy volunteers aged 17 to 70 who are volunteering crew or passengers on participating boats can join, and participation is by invitation. If you join, you’ll wear sensors on the boat and on your body and use a smartphone app to record any pain daily. You’ll be part of regular work days, not a special experiment, and there won’t be any medical treatment changes. Data are collected confidentially and shared in a secure way, with personal details made anonymous. The study is not a drug or device trial, and results are expected after an extended period of data collection, with completion around mid-2027.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Volunteering crew or passengers working onboard or being transported in a professional capacity onboard boats used by the participating agencies and organizations
- Exclusion Criteria:
- • • Nonvolunteering
About Göteborg University
Göteborg University, a leading academic institution in Sweden, is committed to advancing healthcare through innovative research and clinical trials. With a strong focus on interdisciplinary collaboration, the university leverages its extensive expertise in various fields, including medicine, pharmacology, and social sciences, to address pressing health challenges. By sponsoring clinical trials, Göteborg University aims to contribute to the development of new therapies and improve patient outcomes, while adhering to the highest ethical standards and regulatory requirements. Their dedication to rigorous scientific inquiry and community engagement positions them as a pivotal player in the global health research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gothenburg, Sweden
Patients applied
Trial Officials
Stephen D Myers, Professor
Study Chair
University of Chichester, Professor of Exercise Physiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials